Similar mechanisms were also found in prostate cancer, where EVs contributed to docetaxel resistance [34], and ovarian cancer where EVs can deliver vascular-endothelial growth factor (VEGF) into endothelial cells causing resistance to anti-VEGF therapies [35]. This evidence concerns the gene VEGFA and prostate carcinoma.